156 related articles for article (PubMed ID: 34991106)
1. Efficacy and Safety of Trastuzumab Biosimilar (CT-P6) Compared With Reference Trastuzumab in Patients With HER2-positive Advanced Gastric Cancer: A Retrospective Analysis.
Park JH; Yeo JH; Kim YS; Park I; Ahn HK; Cho EK; Shin DB; Yang JY; Kim HS; Lee WK; Sym SJ
Am J Clin Oncol; 2022 Feb; 45(2):61-65. PubMed ID: 34991106
[TBL] [Abstract][Full Text] [Related]
2. ABP 980: A Trastuzumab Biosimilar.
Dhillon S
BioDrugs; 2018 Oct; 32(5):511-514. PubMed ID: 30264234
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of biosimilar trastuzumab (CT-P6) in routine clinical practice in the Republic of Korea: a real-world post-marketing surveillance study.
Park MH; Seo JH; Park JH; Seong MK; Park KU; Kim MK; Chang M; Koh SJ; Lee MH; Lim ST; Yoo YB; Oh SY; Kim SH; Ahn KY; Park TH; Ju H; Baek EH; Kim S; Kim N; Lee E; Kim TH
Expert Opin Biol Ther; 2024 Apr; 24(4):305-312. PubMed ID: 38664937
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of the trastuzumab biosimilar candidate CT-P6.
Esteva FJ; Saeki T; Kim H; Stebbing J
Future Oncol; 2018 Aug; 14(19):1909-1919. PubMed ID: 29482364
[TBL] [Abstract][Full Text] [Related]
5. Predictive Roles of HER2 Gene Amplification and Neutrophil-to-Lymphocyte Ratio on Survival in HER2-Positive Advanced Gastric Cancer Treated With Trastuzumab-Based Chemotherapy.
Park JH; Yeo JH; Kim YS; Park I; Ahn HK; Shin DB; Lee WK; Yang JY; Kim HS; Sym SJ
Am J Clin Oncol; 2021 Jun; 44(6):232-238. PubMed ID: 33710139
[TBL] [Abstract][Full Text] [Related]
6. SB3 (Ontruzant
Lamb YN
BioDrugs; 2018 Jun; 32(3):293-296. PubMed ID: 29796993
[TBL] [Abstract][Full Text] [Related]
7. PF-05280014: A Trastuzumab Biosimilar.
Paik J
BioDrugs; 2018 Oct; 32(5):515-518. PubMed ID: 30280367
[TBL] [Abstract][Full Text] [Related]
8. Clinical development of CT-P6 in HER2 positive breast cancer.
Fu C; Stebbing J; Esteva FJ
Expert Opin Biol Ther; 2019 Oct; 19(10):987-992. PubMed ID: 31507219
[No Abstract] [Full Text] [Related]
9. Poor efficacy response to trastuzumab therapy in advanced gastric cancer with homogeneous HER2 positive and non-intestinal type.
Xu C; Liu Y; Jiang D; Li Q; Ge X; Zhang Y; Huang J; Su J; Ji Y; Hou J; Lu S; Hou Y; Liu T
Oncotarget; 2017 May; 8(20):33185-33196. PubMed ID: 28388541
[TBL] [Abstract][Full Text] [Related]
10. Effect of a Proposed Trastuzumab Biosimilar Compared With Trastuzumab on Overall Response Rate in Patients With ERBB2 (HER2)-Positive Metastatic Breast Cancer: A Randomized Clinical Trial.
Rugo HS; Barve A; Waller CF; Hernandez-Bronchud M; Herson J; Yuan J; Sharma R; Baczkowski M; Kothekar M; Loganathan S; Manikhas A; Bondarenko I; Mukhametshina G; Nemsadze G; Parra JD; Abesamis-Tiambeng ML; Baramidze K; Akewanlop C; Vynnychenko I; Sriuranpong V; Mamillapalli G; Ray S; Yanez Ruiz EP; Pennella E;
JAMA; 2017 Jan; 317(1):37-47. PubMed ID: 27918780
[TBL] [Abstract][Full Text] [Related]
11. Six-Year Survival Outcomes for Patients with HER2-Positive Early Breast Cancer Treated with CT-P6 or Reference Trastuzumab: Observational Follow-Up Study of a Phase 3 Randomised Controlled Trial.
Stebbing J; Baranau Y; Baryash V; Moiseyenko V; Boliukh D; Antone N; Manikhas A; Chornobai A; Park T; Baek EH; Lee J; Choi J; Kim N; Ahn K; Lee SJ; Kim S
BioDrugs; 2023 May; 37(3):433-440. PubMed ID: 36881323
[TBL] [Abstract][Full Text] [Related]
12. CT-P6 compared with reference trastuzumab for HER2-positive breast cancer: a randomised, double-blind, active-controlled, phase 3 equivalence trial.
Stebbing J; Baranau Y; Baryash V; Manikhas A; Moiseyenko V; Dzagnidze G; Zhavrid E; Boliukh D; Stroyakovskii D; Pikiel J; Eniu A; Komov D; Morar-Bolba G; Li RK; Rusyn A; Lee SJ; Lee SY; Esteva FJ
Lancet Oncol; 2017 Jul; 18(7):917-928. PubMed ID: 28592386
[TBL] [Abstract][Full Text] [Related]
13. Long-term efficacy and safety of CT-P6 versus trastuzumab in patients with HER2-positive early breast cancer: final results from a randomized phase III trial.
Stebbing J; Baranau YV; Baryash V; Manikhas A; Moiseyenko V; Dzagnidze G; Zhavrid E; Boliukh D; Pikiel J; Eniu AE; Li RK; Tiangco B; Lee SJ; Kim S
Breast Cancer Res Treat; 2021 Aug; 188(3):631-640. PubMed ID: 34148205
[TBL] [Abstract][Full Text] [Related]
14. Predictive factors of trastuzumab-based chemotherapy in HER2 positive advanced gastric cancer: a single-center prospective observational study.
Li Q; Li H; Jiang H; Feng Y; Cui Y; Wang Y; Ji Y; Yu Y; Li W; Xu C; Yu S; Zhuang R; Liu T
Clin Transl Oncol; 2018 Jun; 20(6):695-702. PubMed ID: 29168107
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of CT-P6 versus reference trastuzumab in HER2-positive early breast cancer: updated results of a randomised phase 3 trial.
Esteva FJ; Baranau YV; Baryash V; Manikhas A; Moiseyenko V; Dzagnidze G; Zhavrid E; Boliukh D; Stroyakovskiy D; Pikiel J; Eniu AE; Li RK; Rusyn AV; Tiangco B; Lee SJ; Lee SY; Yu SY; Stebbing J
Cancer Chemother Pharmacol; 2019 Oct; 84(4):839-847. PubMed ID: 31428820
[TBL] [Abstract][Full Text] [Related]
16. Genomic Profiling of HER2-Positive Gastric Cancer: PI3K/Akt/mTOR Pathway as Predictor of Outcomes in HER2-Positive Advanced Gastric Cancer Treated with Trastuzumab.
Díaz-Serrano A; Angulo B; Dominguez C; Pazo-Cid R; Salud A; Jiménez-Fonseca P; Leon A; Galan MC; Alsina M; Rivera F; Plaza JC; Paz-Ares L; Lopez-Rios F; Gómez-Martín C
Oncologist; 2018 Sep; 23(9):1092-1102. PubMed ID: 29700210
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of CT-P6 (trastuzumab biosimilar) versus reference trastuzumab in combination with pertuzumab in HER2-positive early-stage breast cancer: Preclinical and real-life clinical data.
Bernat-Peguera A; Trigueros M; Ferrando-Díez A; Ibáñez C; Bystrup S; Martínez-Cardús A; Margelí M; Martínez-Balibrea E
Breast; 2022 Apr; 62():1-9. PubMed ID: 35078146
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and Safety of Trastuzumab in Combination with S-1 and Cisplatin Therapy for Japanese Patients with HER2-Positive Advanced Gastric Cancer: Retrospective Analysis.
Okita A; Imai H; Takahashi M; Takahashi H; Umegaki S; Kawamura Y; Hiraide S; Ouchi K; Sato Y; Okada Y; Komine K; Saijo K; Takahashi S; Takahashi M; Shirota H; Ohori H; Gamoh M; Ishioka C
Tohoku J Exp Med; 2018 Jun; 245(2):123-129. PubMed ID: 29937450
[TBL] [Abstract][Full Text] [Related]
19. Totality of Scientific Evidence in the Development of ABP 980, a Biosimilar to Trastuzumab.
Kolberg HC; Colleoni M; Santi P; Demetriou GS; Segui-Palmer MA; Fujiwara Y; Hurvitz SA; Hanes V
Target Oncol; 2019 Dec; 14(6):647-656. PubMed ID: 31620980
[TBL] [Abstract][Full Text] [Related]
20. A prospective observational study on the optimal maintenance strategy in HER2-positive advanced gastric cancer treated with trastuzumab-based therapy.
Li Q; Lv M; Jiang H; Wang Y; Yu S; Li W; Yu Y; Liu T
J Cancer Res Clin Oncol; 2020 Jan; 146(1):287-295. PubMed ID: 31667572
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
